EUVIMEDEUVIMED entdecken
FallberichtOpen Access

The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report

Caitlyn H Livingston, Benjamin Harper

Cureus · 05.08.2024

DOI: 10.7759/cureus.66240 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cureus, erschienen am 05.08.2024. Verfasst von Caitlyn H Livingston und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscinces, Texas A&M University, College Station, USA. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

adenocarcinoma lungbone metastasisegfr exon 19 mutationosimertinibtargeted treatment

Autor:innen und Institutionen

  • Neuroscinces, Texas A&M University, College Station, USA.
  • Medical Oncology, Calvary Mater, Newcastle, AUS.

Zitieren

APA

Livingston, C. H., & Harper, B. (2024). The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report. Cureus. https://doi.org/10.7759/cureus.66240

Vancouver

Livingston CH, Harper B. The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report. Cureus. 2024. doi:10.7759/cureus.66240

BibTeX
@article{Livingston2024,
  author = {Livingston, Caitlyn H and Harper, Benjamin},
  title = {The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report},
  journal = {Cureus},
  year = {2024},
  doi = {10.7759/cureus.66240}
}
Kostenlos starten →